The best drug to every cancer patient

The best drug to every cancer patient

We are ready to take precision medicine to the next level

Oncosyne provides world-leading predictive tumoroid drug screening tools for colorectal and pancreatic cancer, creating new opportunities for pharma companies to accelerate drug discovery and development and for oncologists to select the best drug for each patient.

Oncosyne’s tumoroid platform iCAN is a groundbreaking innovation poised to take precision medicine to the next level. iCAN is marketed for drug discovery and development and is under development for predictive diagnostics in cancer care.

Our vision is to provide game-changing, functional diagnostic tools that help give cancer patients significantly better and longer lives across the globe.

We are ready to take precision medicine to the next level

Oncosyne provides world-leading predictive tumoroid drug screening tools for colorectal and pancreatic cancer, creating new opportunities for pharma companies to accelerate drug discovery and development and for oncologists to select the best drug for each patient.

Oncosyne’s tumoroid platform iCAN is a groundbreaking innovation poised to take precision medicine to the next level. iCAN is marketed for drug discovery and development and is under development for predictive diagnostics in cancer care.

Our vision is to provide game-changing, functional diagnostic tools that help give cancer patients significantly better and longer lives across the globe.

Meet our dedicated team

Jarle Bruun

CEO and co-founder

Jarle Bruun is a passionate translational cancer researcher turned entrepreneur with extensive hands-on experience with relevant cutting-edge technologies in genomics, cell biology, molecular pathology, high-throughput imaging, and drug screening in translational projects.

He holds a PhD in cell biology, genetics and molecular pathology from the University of Oslo.

Peter W. Eide

CTO and co-founder

Peter W. Eide is driven to apply innovative biotechnology to improve society and build new industries. In 2019, he was granted the “Young Researcher” award from Norsk Onkologisk Forum for his research into genomics and drug screening as future tools for patient clinical stratification.

He holds an MSc in cell biology and a PhD in translational bioinformatics focused on computational oncology from the University of Oslo.

Christer Anker Andreassen

Product developer

Christer Anker Andreassen is a wet-lab product developer passionate about handcrafting new functional methods into products that can help cancer patients.

He holds an MSc in cell biology from the University of Oslo.

Nicolas Pasquier pipetting

Nicolas Pasquier

Scientist

Nicolas Pasquier is an ambitious engineer that combines wet-lab expertise with analytic skills. He will drive the pancreatic cancer research and development.

He holds MEng/MSc from ESPCI Paris and a PhD in cell biology from University of Turku / Institut Gustave Roussy.

Advisory board

  • Thomas Andersson – Business advisor
    Senior Business Advisor, Oslo Cancer Cluster Incubator
  • Janne Nestvold – Business advisor
    COO, Oslo Cancer Cluster Incubator
  • Øyvind Bruland – Clinical advisor
    Professor of Clinical Oncology Faculty of Medicine University of Oslo
  • Åke Andrén-Sandberg – Clinical advisor
    Professor emeritus, Division of hepatobiliary and pancreatic surgery, Karolinska University Hospital
  • Anette Sjøgren – Regulatory advisor
    CEO Preventia AB, Sweden